Axonics initiated with an Outperform at Wells Fargo

Wells Fargo analyst Larry Biegelsen started Axonics (AXNX) with an Outperform rating and $22 price target. Historically, the sacral neuromodulationcategory has been a one-player market but he believes Axonics – when FDA approved – will be able to take share from Medtronic (MDT) and help catalyze broader SNM market growth and penetration.
https://thefly.com/landingPageNews.php?id=2827703